Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valaciclovir hydrochloride, quantity: 1222.43 mg (equivalent: valaciclovir, qty 1000 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of recurrent herpes labialis (cold sores). for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with vaclovir, it is recommended that patients use safer sex practices (see section 4.4). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valaciclovir hydrochloride, quantity: 305.61 mg (equivalent: valaciclovir, qty 250 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of recurrent herpes labialis (cold sores). for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with vaclovir, it is recommended that patients use safer sex practices (see section 4.4). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valaciclovir hydrochloride -

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride monohydrate, quantity: 584 mg - tablet, film coated - excipient ingredients: indigo carmine aluminium lake; titanium dioxide; colloidal anhydrous silica; hypromellose; stearic acid; macrogol 8000 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. . for the treatment of ophthalmic zoster. . for the treatment of recurrent herpes labialis (cold sores) . for the treatment of clinical episodes of genital herpes simplex infections. . for the prevention of recurrent genital herpes in immunocompromised patients. . prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride monohydrate, quantity: 1168 mg - tablet, film coated - excipient ingredients: hypromellose; colloidal anhydrous silica; stearic acid; macrogol 8000; titanium dioxide - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. . for the treatment of ophthalmic zoster. . for the treatment of recurrent herpes labialis (cold sores) . for the treatment of clinical episodes of genital herpes simplex infections. . for the prevention of recurrent genital herpes in immunocompromised patients. . prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - valaciclovir hydrochloride monohydrate 1223.4mg equivalent to valaciclovir base 1000 mg - film coated tablet - 1000 mg - active: valaciclovir hydrochloride monohydrate 1223.4mg equivalent to valaciclovir base 1000 mg excipient: magnesium stearate microcrystalline cellulose opadry white y-5-7068 povidone - valaciclovir actavis is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster - associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - valaciclovir hydrochloride monohydrate 305.85mg equivalent to valaciclovir base 250 mg - film coated tablet - 250 mg - active: valaciclovir hydrochloride monohydrate 305.85mg equivalent to valaciclovir base 250 mg excipient: magnesium stearate microcrystalline cellulose opadry white y-5-7068 povidone - valaciclovir actavis is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster - associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - valaciclovir hydrochloride monohydrate 611.7mg equivalent to valaciclovir base 500 mg - film coated tablet - 500 mg - active: valaciclovir hydrochloride monohydrate 611.7mg equivalent to valaciclovir base 500 mg excipient: magnesium stearate microcrystalline cellulose opadry white y-5-7068 povidone - valaciclovir actavis is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster - associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride, quantity: 1112 mg (equivalent: valaciclovir, qty 1000 mg) - tablet, film coated - excipient ingredients: carnauba wax; crospovidone; microcrystalline cellulose; colloidal anhydrous silica; povidone; magnesium stearate; colour - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of recurrent herpes labialis (cold sores) for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valtrex, it is recommended that patients use safer sex practices. (see precautions). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - valaciclovir hydrochloride monohydrate - film coated tablet - 250 milligram